Warts – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Warts
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Warts – Pipeline Review, H1 2019 provides comprehensive
information on the therapeutics under development for Warts (Infectious
Disease), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Warts (Infectious Disease) pipeline guide
also reviews of key players involved in therapeutic development for
Warts and features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3,
14, 3, 5 and 2 respectively. Similarly, the Universities portfolio in
Phase II and Preclinical stages comprises 2 and 1 molecules,
respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Warts (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Warts (Infectious
  Disease) by companies and universities/research institutes based on
  information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Warts (Infectious
  Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Warts (Infectious Disease) therapeutics
  based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Warts (Infectious Disease)

Reasons to buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Warts (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Warts (Infectious Disease) pipeline depth and focus of Indication
  therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Key Topics Covered

1. Introduction
2. Warts – Overview
3. Warts – Therapeutics Development
4. Warts – Therapeutics Assessment
5. Warts – Companies Involved in Therapeutics Development
6. Warts – Drug Profiles
7. Warts – Dormant Projects
8. Warts – Discontinued Products
9. Warts – Product Development Milestones
10. Appendix

Companies Mentioned

• Aclaris Therapeutics Inc
• Cutanea Life Sciences Inc
• Cytovation AS
• G&E Corp
• Genetic Immunity Inc
• Laboratories Ojer Pharma SL
• LEO Pharma A/S
• Maruho Co Ltd
• Nielsen Biosciences Inc
• Novan Inc
• Novartis AG
• Pfizer Inc
• Phio Pharmaceuticals Corp
• Promius Pharma LLC
• Tamir Biotechnology Inc
• Verrica Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m9l8i9

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Dermatological
Drugs